Tags : ECTRIMS 2021

Clinical Trials

Sanofi Presents Results of Tolebrutinib in a P-IIb LTS for

Shots: The P-IIb LTS part A assesses tolebrutinib (5/15/30/60mg/day) in patients with RMS and in Part B, where all participants switched to the 60mg The study demonstrated a reduction in MS disease activity as MRI and showed a favorable 1yrs. tolerability. “Mean EDSS scores across treatment groups ranged from 2.18 to 2.65 at baseline and remained relatively stable over […]Read More